HC Wainwright set a $30.00 price target on Omeros (NASDAQ:OMER) in a research report released on Monday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Several other equities research analysts have also commented on OMER. Cowen lowered Omeros from an outperform rating to a market perform rating in a research note on Thursday, November 2nd. Zacks Investment Research raised Omeros from a sell rating to a hold rating in a research note on Wednesday, November 15th. Maxim Group reissued a buy rating and set a $24.00 price target on shares of Omeros in a research note on Monday, November 6th. Wedbush reissued an outperform rating and set a $47.00 price target on shares of Omeros in a research note on Tuesday, November 28th. Finally, ValuEngine raised Omeros from a sell rating to a hold rating in a research note on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Omeros currently has an average rating of Buy and a consensus target price of $30.38.
Shares of Omeros (OMER) opened at $11.01 on Monday. Omeros has a twelve month low of $10.52 and a twelve month high of $27.09. The firm has a market capitalization of $528.52, a P/E ratio of -8.53 and a beta of 3.30. The company has a debt-to-equity ratio of 8.99, a current ratio of 4.77 and a quick ratio of 4.74.
Several large investors have recently made changes to their positions in OMER. Alliancebernstein L.P. boosted its stake in shares of Omeros by 40.1% during the 2nd quarter. Alliancebernstein L.P. now owns 61,500 shares of the biopharmaceutical company’s stock worth $1,224,000 after acquiring an additional 17,600 shares in the last quarter. TIAA CREF Investment Management LLC raised its position in shares of Omeros by 39.4% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 149,252 shares of the biopharmaceutical company’s stock worth $2,971,000 after purchasing an additional 42,165 shares during the last quarter. Ameriprise Financial Inc. acquired a new position in shares of Omeros during the 2nd quarter worth approximately $971,000. Northern Trust Corp raised its position in shares of Omeros by 6.4% during the 2nd quarter. Northern Trust Corp now owns 572,576 shares of the biopharmaceutical company’s stock worth $11,397,000 after purchasing an additional 34,328 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Omeros by 5.4% during the 2nd quarter. Vanguard Group Inc. now owns 1,825,671 shares of the biopharmaceutical company’s stock worth $36,341,000 after purchasing an additional 94,280 shares during the last quarter. 50.95% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Omeros (OMER) PT Set at $30.00 by HC Wainwright” was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://stocknewstimes.com/2018/02/20/omeros-omer-pt-set-at-30-00-by-hc-wainwright.html.
Omeros Company Profile
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.